Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

SYMPATICO Evaluates Frontline Ibrutinib and Venetoclax Combo in MCL

September 14th 2020

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

Novel Combos Are Shaking Up the CLL Landscape

September 15th 2019

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

Myelofibrosis Management Makes Strides With JAK Inhibitors, But Work Remains

September 15th 2019

Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Tisagenlecleucel Maintains Efficacy in Real-World Setting

September 15th 2019

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell Lymphoma

September 14th 2019

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

September 14th 2019

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Update Spotlights Tisagenlecleucel Developments in DLBCL

September 14th 2019

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

Despite Challenges, Targeted Cellular Therapies Continue to Be Explored in AML

September 13th 2019

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

Checkpoint Inhibition Before HSCT Improves PFS Without Increasing Toxicity in R/R Hodgkin Lymphoma

September 13th 2019

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

x